Call Options

14 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$51.17 - $68.18 $7.77 Million - $10.4 Million
-151,900 Reduced 69.52%
66,600 $3.6 Million
Q1 2024

May 15, 2024

BUY
$60.67 - $89.12 $3.49 Million - $5.13 Million
57,600 Added 35.8%
218,500 $14.9 Million
Q4 2023

Feb 14, 2024

BUY
$38.62 - $72.18 $2.64 Million - $4.94 Million
68,400 Added 73.95%
160,900 $10.1 Million
Q2 2023

Aug 14, 2023

SELL
$43.47 - $67.77 $782,460 - $1.22 Million
-18,000 Reduced 16.29%
92,500 $5.19 Million
Q1 2023

May 15, 2023

SELL
$41.0 - $56.12 $1.55 Million - $2.13 Million
-37,900 Reduced 25.54%
110,500 $5 Million
Q4 2022

Feb 14, 2023

BUY
$39.19 - $65.67 $1.27 Million - $2.13 Million
32,500 Added 28.04%
148,400 $6.03 Million
Q2 2022

Aug 15, 2022

BUY
$43.23 - $73.83 $2.08 Million - $3.54 Million
48,000 Added 70.69%
115,900 $7.04 Million
Q1 2022

May 16, 2022

SELL
$53.19 - $79.24 $106,380 - $158,480
-2,000 Reduced 2.86%
67,900 $4.26 Million
Q4 2021

Feb 14, 2022

BUY
$70.09 - $111.29 $1.39 Million - $2.21 Million
19,900 Added 39.8%
69,900 $5.3 Million
Q3 2021

Nov 15, 2021

BUY
$110.2 - $156.64 $1.1 Million - $1.57 Million
10,000 Added 25.0%
50,000 $5.6 Million
Q2 2021

Aug 16, 2021

BUY
$100.84 - $161.89 $3.03 Million - $4.86 Million
30,000 Added 300.0%
40,000 $6.48 Million
Q1 2021

May 17, 2021

SELL
$110.72 - $210.04 $1.11 Million - $2.1 Million
-10,000 Reduced 50.0%
10,000 $1.22 Million
Q4 2020

Feb 16, 2021

BUY
$79.67 - $173.23 $796,700 - $1.73 Million
10,000 Added 100.0%
20,000 $3.06 Million
Q4 2019

Feb 14, 2020

BUY
$36.68 - $73.13 $366,800 - $731,300
10,000 New
10,000 $609,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $4.05B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.